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Abstract

Author Manuscript

The canonical model of RB-mediated tumour suppression developed over the past 30 years is
based on the regulation of E2F transcription factors to restrict cell cycle progression. Several
additional functions have been proposed for RB, on the basis of which a non-canonical RB
pathway can be described. Mechanistically, the non-canonical RB pathway promotes histone
modification and regulates chromosome structure in a manner distinct from cell cycle regulation.
These functions have implications for chemotherapy response and resistance to targeted anticancer
agents. This Opinion offers a framework to guide future studies of RB in basic and clinical
research.

Author Manuscript

The mechanism by which RB interacts with E2F family members E2F1–E2F5 to regulate
cell cycle entry has been studied in great detail1–3. In its simplest form, RB represses
transcription of E2F family member target genes in the G1 phase of the cell cycle1–3.
Transcriptional repression in this paradigm occurs through RB binding to the transactivation
domain of these E2Fs. Heterodimerization of the respective E2F family member with a
dimeric partner (DP) subunit localizes this complex to E2F target gene promoters that
contain the consensus DNA binding element TTTCGCGC1–3 (FIG. 1a). Growth factor
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signals stimulate the assembly and activation of cyclin D and its associated cyclin-dependent
kinases (CDK4 or CDK6) that initially phosphorylate RB in the G1 phase of the cell
cycle1–3. Cyclin E-CDK2 complexes phosphorylate RB in late G1, which releases the
respective E2F family member from RB, leading to the activation of transcriptional targets
to advance the cell cycle1–3 (FIG. 1a). Frequent genome alterations affecting the function of
RB, cyclins, CDKs and CDK inhibitors have underscored the central importance of this
regulatory mechanism in cancer, a circuit that has become known as the RB pathway4,5
(BOX 1). The abundance of mutations affecting members of this pathway, and the resulting
lack of proliferative control, has led to the idea that RB pathway disruption is a hallmark of
cancer6. In this article, we refer to RB-E2F transcriptional control that is regulated by cyclinCDK complexes as the canonical function of RB (FIG. 1a).

Author Manuscript
Author Manuscript

Biochemical experiments and clinical studies alike have generated data that are not easily
reconciled with the canonical RB pathway. For example, chromatin immunoprecipitation
and sequencing (ChIP-seq) studies have revealed that RB occupies not only E2F-regulated
gene promoters but also transcriptional enhancers and repetitive DNA sequences7–9. Several
studies have also detected RB complexes on chromatin in S phase, even though
hyperphosphorylation of RB by CDKs has been previously shown to decrease binding of RB
to E2F target gene promoters10–13. In addition, multiple clinical studies have indicated that
loss of RB protein expression, as opposed to alterations of other RB pathway components, is
uniquely correlated with improved response to chemotherapeutics3,14–20. Further, different
cancer types often show mutations of unique RB pathway components, suggesting that the
effects of mutations in different RB pathway components are not functionally equivalent3. In
some cancers, RB1 gene loss has also been observed to occur later in disease
progression21–24 or is found more prevalently in metastasis25–27, when deregulated cell
proliferation has already been established. Although RB-like protein 1 (RBL1, also known
as p107) and RBL2 (also known as p130) also regulate E2F and the cell cycle, mutations
inactivating the encoding genes are less common in tumours than mutations inactivating
RB1 (REFS23,24,28). Similarly, engineered mutations in the murine Rbl1 and Rbl2 genes
give weaker tumour phenotypes than mutations in Rbl (REF2). Each of these observations
has several potential explanations, which are not fully explored in this article. Overall,
however, they suggest that RB has functions that extend beyond the control of classic E2F
targets or the regulation of cell proliferation. Importantly, these functions may be clinically
relevant for patients with cancer.

Author Manuscript

Mechanistic studies have also revealed that RB has a multitude of molecular functions.
These functions involve the regulation of inflammation29, mitochondria and
metabolism30,31, autophagy32, apoptosis33 and stemness34,35. Importantly, these functions
have been linked to CDK-dependent E2F target gene transcription and cell cycle
regulation31,36,37 and thus are related to the canonical RB pathway. Still, one simple fact
about RB is obscured by the complexity of available studies, which is that RB is primarily
located in the nucleus and associated with chromatin38. The pool of RB that controls cell
cycle progression through targeting of E2F-regulated promoters (the canonical RB function)
(FIG. 1a) is undoubtedly one important facet of RB action. In this article, we propose that
there is a second pool of chromatin-associated RB that performs non-canonical functions.
This non-canonical activity of RB impacts the organization of heterochromatin, promotes
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chromosome integrity and may be independent of CDK-mediated RB phosphorylation. We
propose that this second pool of RB may help to explain many of the features of RB activity
that do not fit with canonical RB pathway regulation. Importantly, this non-canonical
activity of RB may explain recent data on the effects of RB loss and their impact on
therapeutic response and acquired resistance14,16–27. We appreciate that the molecular
details of the non-canonical functions of RB are still poorly understood and that, therefore,
categorizing RB-dependent phenotypes as the result of canonical or non-canonical RB
activities is an imperfect approach. Nevertheless, we hope that this interpretation of the RB
literature will help to stimulate the appreciation and investigation into a largely unexplored
area of cancer biology and complement our current knowledge of the role of RB in cell cycle
control.

RB function in proliferating cells
Author Manuscript

The current understanding of RB has long been shaped by the concept that phosphorylation
on multiple sites by cyclin D-associated and cyclin E-associated CDKs, so-called
hyperphosphorylation, leads to dissociation of RB from chromatin at the beginning of S
phase and supposedly renders it functionless for the remainder of the cell cycle28. Results
showing that RB loss affects the biology of proliferating cells suggest that this model is
incomplete and that RB retains activity even in cells that have high CDK activity and in
which RB is phosphorylated. There are several mechanisms that may explain how RB
retains activity in these conditions, as described below.
RB can be protected from phosphorylation-dependent effects.

Author Manuscript

Most cyclin-CDK complexes require a basic amino acid patch near the carboxyl terminus of
RB to dock and recognize it as a substrate39. A number of studies have described acetylation
or methylation of lysine residues in this patch that may inhibit CDK recognition and RB
phosphorylation40–42. In addition, serine/threonine-protein phosphatase 2 (PP2) has been
observed to protect RB from phosphorylation-dependent dissociation from chromatin in S
phase10. Protein phosphatase 1 (PP1) has also been shown to recognize a peptide motif that
overlaps with the cyclin docking site in the carboxyl terminus of RB43. This not only
facilitates dephosphorylation but also sterically inhibits cyclin-CDK recognition and
therefore phosphorylation of RB (FIG. 1b). Collectively, these studies illustrate that
mechanisms exist to protect RB from the inactivating effects of CDKs, even when CDK
activity is high at the end of G1 and during S phase.
Hyperphosphorylated RB can bind E2F1.

Author Manuscript

It has also been demonstrated that RB retains some function when hyperphosphorylated by
CDKs. RB interacts with transcription factor E2F1 through molecular contacts, in particular,
via the marked box domain of E2F1 (REFS13,44,45). This interaction is resistant to disruption
by CDK phosphorylation, allowing some sites on RB to be phosphorylated without
disrupting this interaction13,46. This interaction between RB and E2F1 results in histone H3
lysine 27 trimethylation (H3K27me3) at repetitive genomic sequences7. By contrast, the
interaction of RB with other E2F family members is disrupted by CDK-mediated
phosphorylation, thereby promoting E2F gene transcription28. Crystal structures of RBL1
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interacting with the marked box domain of E2F5 reveal that the respective interaction site
contains a CDK phosphorylation site, whereas the RB-E2F1 marked box interaction site
does not contain a CDK phosphorylation site47, suggesting a reason why this complex is not
disrupted by CDK activity. Also, the RB-E2F1 complex has low binding affinity for a
consensus E2F promoter DNA element compared with the high binding affinity of E2F1 in
uncomplexed form48,49, suggesting a reason why RB-E2F1 complexes in S phase do not
bind to and regulate E2F target genes. These data argue for a qualitatively unique interaction
between RB and E2F1 that is not shared with other E2F family proteins. Importantly, a
mutant mouse line bearing an F832A substitution in its RB protein is unable to form this
unique RB-E2F1 interaction7. Cells from these mice possess normal regulation of E2F target
genes, enter into S phase normally but misexpress repetitive sequences and are cancer
prone7. This result highlights the surprising impact of the CDK-resistant interaction of RB
with E2F1.

Author Manuscript

It has also recently been demonstrated that phosphorylation of RB by p38 MAPK on a site
distinct from the E2F1 interaction site can actually stimulate E2F1 binding to RB at yet
another location in the RB polypeptide and lead to complex formation at promoter regions of
E2F target genes50. This p38 MAPK phosphorylation event bypasses CDK control of RB
and thus offers another mechanistic explanation for RB function that occurs in the presence
of high CDK activity and hyperphosphorylation (FIG. 1c).
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Overall, protection from CDK phosphorylation and retention of function after CDK
phosphorylation are emerging concepts in RB research. It has also been demonstrated that
hyperphosphorylated RB takes on new functions in regulating AKT-dependent signal
transduction that monophosphorylated or unphosphorylated RB does not have51; although
this study focused on RB interactions that occur in the cytoplasm, it is possible that
additional interactions of nuclear RB are also stimulated by phosphorylation.
Chromatin replication preserves RB-dependent epigenetic marks.

Author Manuscript

An important but indirect mechanism that explains retention of RB function in S phase is
inherent to chromatin replication mechanisms. Even though RB-E2F complexes are
extensively disassembled at S phase entry, it is known that RB recruits epigenetic proteins
such as the histone methyltransferase enhancer of zeste homologue 2 (EZH2) to direct
H3K27me3 deposition at transcriptional enhancers and promoters of genes encoding the
stem cell factors octamer-binding protein 4 (OCT4; also known as POU5F1) and SOX2
using a CDK-sensitive interaction with E2Fs7,8,52. This heterochromatin pattern is then
preserved in S phase during DNA replication53,54. In turn, H3K27me3 locations are
reinforced in daughter cells through another round of EZH2 recruitment by RB in the
ensuing G1 (FIG. 1d). In this way, mechanisms that perpetuate epigenetic memory during
DNA replication may sustain RB-dependent features without requiring the continuous
physical presence of RB protein.
In sum, these studies indicate that RB can be protected from high levels of CDK activity
(thereby maintaining a pool of hypophosphorylated RB), that hyperphosphorylated RB can
retain function and that RB-dependent histone modification patterns are preserved
throughout the cell cycle. These characteristics allow RB to exert activities in proliferating
Nat Rev Cancer. Author manuscript; available in PMC 2019 August 14.
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cells, for example, to shape cell-lineage commitment55. The ability of RB to function in a
manner that is resistant to G1-S cell cycle regulation is fundamental to the epigenetic and
chromosome structure functions that we discuss in this article.

RB maintains genome stability
RB occupies diverse genome locations.

Author Manuscript

E2F binding sites are often located in proximal promoters, and the canonical function of RB
involves cell cycle-dependent chromatin changes in this local environment as part of the
transcriptional control mechanism56. RB is able to localize to the genome in a sequenceindependent manner, and this has come into focus with the discovery that non-homologous
end joining57 (NHEJ) and homologous recombination58 (HR) repair mechanisms require RB
for maximal function (FIG. 2a). These studies established that RB is physically recruited to
the sites of DNA breaks during the repair process57,58. In a complementary manner, studies
using ChIP-seq demonstrated that RB is targeted to many different genomic locations such
as gene bodies during transcription9, transcriptional enhancers8 and broad categories of
repetitive DNA elements including long interspersed nuclear elements (LINEs) and satellite
repeats7,59,60.
E2F1 participates in the genome-wide roles of RB.
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Although the targeting of RB to repetitive sequences and sites of DNA damage does not
seem to require the consensus E2F element (TTTCGCGC), mechanistic studies show that
RB often associates with these genome locations in a manner that depends on E2F1
(REFS7,58). Indeed, E2F1 is also recruited to sites of double-strand breaks58,61 and is
essential for NHEJ61, HR58, fidelity of DNA replication, chromosome condensation59 and
RB-dependent H3K27me3 deposition at repetitive sequences even without the presence of a
consensus DNA binding site7. A mutation in RB that cripples its marked box domain
interaction with E2F1 has been shown to disrupt binding of both RB and E2F1 to diverse
categories of repetitive sequences7,59. The cooperative relationship between RB and E2F1 in
localizing to repetitive sequences59 or to DNA breaks58, in which neither can localize
without the other, might be mechanistically enabled by formation of the CDK
phosphorylation-resistant RB-E2F1 complex59 (FIG. 1c). RB acetylation and methylation
are induced by DNA damage40–42,62, and these modifications reduce CDK phosphorylation
of RB42, further indicating that RB-E2F1 complexes may be sheltered from CDK activity
when engaged in NHEJ and HR functions. Hyperphosphorylated RB also interacts with
E2F1 in response to DNA breaks12,63. These observations further implicate RB-E2F1
interactions that are insensitive to CDK activity (FIG. 1). Although the E2F1 protein is
capable of stimulating proliferation through activation of transcription of E2F target genes in
a manner similar to other E2Fs, the effect of E2F1 loss is unique among E2Fs, as
spontaneous DNA damage arises in response to E2F1 loss64, and E2f1-knockout mice are
susceptible to cancer65; these effects are not observed when other E2F family members are
inactivated66. For this reason, we consider these RB-E2F1-dependent epigenetic and genome
stability roles as CDK-independent and as part of a non-canonical category of functions.
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Once recruited to genomic repeats or DNA breaks, RB recruits regulators of chromatin
structure that facilitate remodelling and higher-order packaging. At double-stranded DNA
breaks, RB interacts with DNA end-binding proteins X-ray repair cross-complementing
protein 5 (XRCC5) and XRCC6 to facilitate repair of DNA breaks through end joining57. In
HR repair, RB recruits the DNA helicase transcription activator BRG1 to relax chromatin
structure and promote end resection as part of the repair process58. Striking similarities have
also been reported for mutants in the Arabidopsis spp. gene RBR1 (retinoblastoma-related
1), where RBR1 is required for recruitment of HR factors to sites of DNA breaks67,68. RB
facilitates heterochromatin formation through recruitment of histone deacetylase complexes
such as the nucleosome-remodelling and deacetylase (NuRD) complex and histone
methyltransferases such as EZH2 to deacetylate and trimethylate H3K27 at repetitive
sequences such as LINEs and satellites, leading to the silencing of their expression7,69.

Author Manuscript

RB-dependent deposition of H4K20me3 at centromeric and telomeric regions contributes to
heterochromatin formation, recruitment of the structural maintenance of chromosome
complex known as cohesin and genome stability at these regions70–72. On a wholechromosome scale, RB can serve to recruit protein complexes involved in the structural
maintenance of chromatin: condensin II and cohesin70,73. This is critical to the compaction
and segregation of mitotic chromosomes in untransformed cells70,74. It has also been shown
that failure to recruit these factors negatively affects DNA replication patterns earlier in the
cell cycle during S phase and that insufficiently condensed chromosomes and mitotic errors
may in part be due to DNA lesions that originate in defective replication59,70,75,76.
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These studies show that, in addition to regulating proximal E2F-responsive cell cycle gene
promoters, RB is distributed throughout the genome in a sequence-independent manner,
often in complex with E2F1 (FIG. 2a). This leaves the question of how localization to DNA
breaks or repeats is coordinated. A recent report of RB binding to histone H1 may offer
some clues for future research77, but our understanding of this is very much just beginning.
From these locations, RB is poised to participate in many fundamental processes of genome
maintenance including DNA-break repair, DNA replication, chromosome condensation and
heterochromatin formation (FIG. 2b). The diverse functions and molecular partners that RB
uses suggest that additional studies are needed to understand how these partners are selected
and the many functions are coordinated.

Author Manuscript

Importantly, chromosome instability phenotypes have been observed in RB-mutant
embryonic stem cells, where there is no functional G1-S regulation by RB78–80. Because
these repair and epigenetic functions adopt CDK-resistance mechanisms and involve
somewhat direct RB participation (FIG. 1), we infer that the role of RB in these processes
fits best with the non-canonical function of RB. However, it is important to consider that the
well known RB-E2F cell cycle paradigm contributes to the expression of repair factors and
spindle assembly checkpoint components81. We speculate that upon reduced activity of both
canonical and non-canonical RB pathways, cells experience DNA damage and
reorganization of heterochromatin distribution patterns on a genome-wide scale. We suggest
that this state of genetic instability is key to the effects of RB loss on drug sensitivity and
explains the cell-lineage alterations described in the ensuing sections.
Nat Rev Cancer. Author manuscript; available in PMC 2019 August 14.
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RB loss sensitizes to chemotherapy
Defective RB function can influence cellular responses to a variety of cancer treatment
approaches3. Among these, it is noteworthy that agents that serve to block proliferation, such
as hormone receptor antagonists, depend on RB for action15,82,83, while RB-deficient cells
are more sensitive to DNA-damaging agents84–87. We suggest that loss of both canonical
cell cycle control and non-canonical regulation of chromatin structure make cells lacking RB
uniquely sensitive to genotoxic agents3.
RB loss improves chemotherapy and radiation response in lung cancer.

Author Manuscript
Author Manuscript

Analysis of lung adenocarcinomas, the most common form of non-small-cell lung cancer
(NSCLC), offers insight into non-canonical RB roles in treatment response. Deregulated
proliferation is likely influenced by mutations or copy number changes in genes encoding
CDK inhibitor 2A (CDKN2A, also known as p16-INK4A), cyclin D, CDK4, CDK6 and RB
that are commonplace in this cancer88 (BOX 1), and rapid proliferation creates sensitivity to
DNA damage89. Loss of RB, but not other canonical pathway components, however,
correlates with improved response to DNA damage agents85 and longer patient
survival14,18,19. This indicates that RB loss is different from CDKN2A or cyclin-CDK
alterations. Importantly, the proliferation indices of RB-positive and RB-negative, treatment
naive lung adenocarcinomas are similar14, suggesting that differences in response cannot be
explained by proliferation alone. A remarkably similar clinical scenario in which RB loss is
not correlated with elevated levels of proliferation but is associated with unusually long
survival following chemotherapy has been reported in serous ovarian cancer20. Another way
to consider the role of RB in chemotherapy is that DNA damage agents and radiation induce
an RB-dependent G1 cell cycle arrest in RB-positive but not RB-negative cancers3, thus
explaining their sensitivity5,85. However, p53 is upstream of RB in the same DNA damage
response cell cycle arrest checkpoint5, suggesting that failure of the p53-dependent DNA
damage response should similarly increase treatment sensitivity to levels similar to those
observed with RB loss. Because p53 status does not predict chemotherapy responsiveness in
NSCLC85, it seems unlikely that the inability to arrest the cell cycle in response to DNA
damage predicts a strong response to treatment85. Therefore, an alternative possibility for
explaining the observed correlations of RB status and responsiveness to chemotherapy and
DNA-damaging agents draws on the idea that RB has activities that extend beyond its role in
the regulation of cell cycle progression. In particular, RB loss would compromise genome
stability more directly through the roles of RB in promoting DNA repair and chromosome
stability. Thereby, RB loss would create an inherent sensitivity to DNA damage-dependent
therapies.
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For several years the relationship between RB loss and DNA damage sensitivity has
suggested a vulnerability that could be exploited if RB status was used as a guide in
treatment choice3. These treatment response data have been difficult to explain when one
views RB solely as a regulator of cell proliferation. By contrast, the non-canonical functions
of RB provide an explanation that is simpler and more direct. When viewed from the
perspective that RB is distributed throughout the genome and has roles that promote genome
stability, the link between RB status and sensitivity to DNA-damaging agents seems logical.
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The idea that RB deficiency can be used to help predict sensitivity to DNA damage-based
cancer treatment is therefore easily aligned to this mechanism of action.

RB deficiency in targeted therapy

Author Manuscript

Molecularly targeted cancer therapies promise to improve patient outcomes with reduced
side effects by exploiting dependencies or vulnerabilities unique to cancer cells, and RB loss
has been shown to confer resistance to targeted therapies. This is best illustrated by the
reliance of CDK4 or CDK6 inhibitors such as palbociclib on RB function90. Blockade of Dtype cyclin-CDK4 or CDK6 kinase activity is known to require RB for growth arrest91–93,
and these agents were designed to re-activate the canonical RB pathway. However, the
transdifferentiation phenotype of cancers relapsing from a range of molecularly targeted
therapies suggests that RB loss is associated with acquired therapeutic resistance through
means beyond altered cell cycle control. Understanding how RB loss contributes to
resistance will be critical for realizing the potential of these targeted agents.
Resistance to anti-androgens in prostate adenocarcinoma.

Author Manuscript

Prostate cancers are uniquely dependent on the androgen receptor (AR) signalling axis for
growth and survival. A common mechanism of acquired anti-androgen resistance is genetic
alteration of AR itself, leading to persistent and sometimes ligand-independent AR
signalling94. Newer anti-androgens like enzalutamide and abiraterone have been developed
to overcome acquired resistance by improving AR signalling blockade95. However, unique
forms of acquired resistance, characterized by transformation of the original AR-expressing
adenocarcinoma into histological variants lacking AR, are increasingly observed in patients
relapsing from these new anti-androgens96. One type of the AR-deficient variant undergoes
histological transdifferentiation from the luminal epithelial phenotype of the original
adenocarcinoma to a neuroendocrine phenotype97 (FIG. 3a). These treatment-acquired
neuroendocrine prostate cancer variants share clonal origin with the pre-existing
adenocarcinoma, as they contain the same mutations27.

Author Manuscript

RB loss is rare in prostate adenocarcinomas98 but frequent in treatment-acquired
neuroendocrine prostate cancers (NEPCs)96, suggesting that RB loss plays a role in
transdifferentiation or loss of lineage identity. Two recent studies have tested this hypothesis
in engineered mouse models and human prostate cancer cell lines and found a causative
relationship between RB loss and altered cell lineage99,100. Pten mutation in mouse prostate
epithelium generates a weakly metastatic adenocarcinoma that does not transdifferentiate101,
and Rb1 mutation in the same cells does not cause cancer101–103. Prostate cancer cells
deficient in both Pten and Rb1 develop as adenocarcinoma then transition into a mixed
tumour containing both luminal-like and neuroendocrine-like prostate cancer cells,
demonstrating lineage plasticity100. Tumours are highly metastatic and remain sensitive to
anti-androgen therapy but inevitably relapse in a form lacking AR expression, possessing
neuroendocrine markers and often having acquired spontaneous Trp53 mutations100.
Because Rb1 loss does not appreciably alter proliferation of tumour cells in this model100,
the most logical conclusion is that Rb1 loss primarily contributes to lineage plasticity. The
second study used a combination of RNAi and Cas9-mediated gene deletions to inactivate
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RB1 and TP53 in human anti-androgen-sensitive prostate cancer cell lines99. Combined
RB1 and TP53 loss, but not single mutations, led to increased expression of the
reprogramming transcription factor SOX2, and this conferred increased lineage plasticity, as
indicated by upregulation of basal and neuroendocrine lineage markers at the expense of
luminal markers, including AR99. Loss of AR expression was accompanied by acquired
resistance to anti-androgens, and this could be reversed by blocking SOX2 expression99.

Author Manuscript

In both studies, RB loss drove lineage plasticity through de-repression of stem cell and
epigenetic reprogramming factors SOX2 and EZH2 (REFS99,100). Analyses of human
prostate cancer specimens also demonstrate increased expression of SOX2 and EZH2 in
NEPC relative to prostate adenocarcinoma100. Silencing of SOX2 or EZH2 reversed NEPC
transformation and restored sensitivity to anti-androgen therapy100. Small molecule EZH2
inhibitors can also reverse NEPC transformation and anti-androgen resistance100. These
exciting data support a model of epigenetic instability fuelled by RB loss and lineage
plasticity, which is detailed in FIG. 3b. Perhaps more importantly, they also indicate that
acquired resistance to targeted therapies through lineage plasticity is reversible, opening the
door to new therapeutic opportunities. Collectively, these studies offer a mechanistic link
between RB loss, de-repression of epigenetic reprogramming factors, prostate cancer lineage
plasticity and acquired anti-androgen resistance.
RB loss in EGFR inhibitor-resistant lung adenocarcinoma.

Author Manuscript

A very similar story of RB loss and transdifferentiation is emerging in the treatment of lung
adenocarcinoma with epidermal growth factor receptor (EGFR) inhibitors. Specific
activating mutations in EGFR drive tumorigenesis in some patients with lung
adenocarcinoma, and these tumours are sensitive to EGFR tyrosine kinase inhibitors such as
erlotinib104. Analogous to prostate cancer, mechanisms of acquired resistance to EGFR
inhibitors involve alteration of EGFR itself105,106. For example, acquisition of a second site
T790M substitution reduces erlotinib binding and reactivates EGFR signalling105. Newer
EGFR inhibitors like osimertinib specifically inhibit EGFR-T790M107. Although
osimertinib can extend survival in patients who have relapsed after treatment with erlotinib,
beneficial therapeutic responses are often short-lived because target-independent resistance
mechanisms arise108,109.

Author Manuscript

Similar to observations in prostate cancer, an emerging mechanism of resistance in patients
with lung adenocarcinoma who have relapsed after treatment with EGFR inhibitors involves
transformation to histological variants lacking EGFR expression, including variants
expressing neuroendocrine lineage markers and resembling small-cell lung cancer, a lung
tumour subtype that is nearly universally RB1-mutant110 (FIG. 3a). Accordingly, a recent
study has found that RB was lost universally in patients with EGFR-mutant lung
adenocarcinoma who relapsed after treatment with EGFR inhibitors by neuroendocrine
transformation111. In one particularly informative patient, three distinct metastatic tumours
were sampled after relapse, and all shared the EGFR driver mutation of the original
adenocarcinoma. RB1 was lost in both metastatic tumours exhibiting neuroendocrine
transformation but not in a metastatic tumour retaining an adenocarcinoma phenotype that
acquired resistance via the EGFR-T790M alteration. Thus, this study indicates that RB1 loss
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is correlated with neuroendocrine transformation of lung adenocarcinoma during relapse
from EGFR inhibitors, even within the same patient111. Interestingly, cell culture models of
EGFR resistance indicate that induction of SOX2 expression is associated with resistance to
inhibitors112, suggesting that it shares molecular features with prostate lineage plasticity as
well (FIG. 3b). However, whether RB1 loss can be an initiating or contributing factor for
neuroendocrine transformation in lung cancer is unclear, as the described study only shows
correlations and lacks any experimental data to document the direct role of RB1 loss in this
transformation.

Author Manuscript

Taken together, while requiring further substantiation, these studies in prostate and lung
cancer suggest two general pathways of acquired resistance to targeted therapies. One
pathway alters the therapeutic target or engages a compensatory pathway while maintaining
its original cancer phenotype. This is often caused by secondary mutations to the original
therapeutic target, such as the T790M substitution in EGFR. Alternatively, some cancers
acquire resistance through a fundamentally different route in which they lose lineage
commitment, express neuroendocrine markers and no longer express the therapeutic target.
The emerging evidence described above suggests that RB loss is key to lineage plasticity.
Genomic-repeat silencing and lineage plasticity.

Author Manuscript

Widespread de-repression of repetitive genomic sequences, such as satellites and LINE1
elements, has been shown to occur sporadically in a broad spectrum of epithelial cancers113.
In particular, simultaneous expression of diverse repeat classes, including their genomic
neighbours, often implicated in neural or stem cell pathways, has been observed113. This
suggests that global alterations in repeat expression are linked to cell lineage. As described
above, RB is uniquely capable of silencing broad classes of repetitive sequences such as
LINEs and satellites7, and it occupies enhancers to silence expression of the pluripotency
factors OCT4 and SOX2 through recruitment of histone deacetylases and EZH2 to
deacetylate histones and deposit H3K27me38,114. Thus, its non-canonical functions suggest
that RB loss is part of this lineage transformation mechanism (FIG. 3b). A prostate cancer
study examining genes that are responsible for acquired therapeutic resistance to AR
inhibitors further illustrates this concept. Using a patient-derived xenograft model of
acquired resistance, loss of RB and expression of the gene paternally expressed 10 (PEG10)
were identified as coincident with a shift in lineage commitment to NEPC115. PEG10
expression is normally restricted to the placenta, and its complex gene structure is derived
from a retroviral repeat115. In AR-dependent prostate cancer cell lines, PEG10 is repressed
by RB and E2F1, but when expressed in prostate cancer cells deficient in both RB1 and
TP53, it is required for proliferation115.

Author Manuscript

RB loss is coincident with neuroendocrine transdifferentiation in prostate and lung cancer
therapeutic resistance. In addition, the unique molecular mechanisms that RB uses to
suppress expression of pluripotency factors and genomic repeats offer a direct mechanistic
connection to transdifferentiation. At present, our understanding of the molecular events that
underpin the conversion of adenocarcinomas to neuroendocrine tumours during the
acquisition of therapeutic resistance remains in its infancy. However, we suggest that RB
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loss is critical to this process and that disruption of its non-canonical functions best explains
its role in this emerging paradigm of drug resistance.

Conclusions
The studies described in this Opinion provide a number of scenarios for RB function outside
its best-known role in cell cycle control. We suggest that chromatin-associated RB functions
can be collectively organized into a non-canonical RB pathway, and FIG. 4 offers a visual
summary of the features of this emerging pathway compared with the well known role for
RB in cell cycle control.
Comparison of canonical and non-canonical pathways.

Author Manuscript

The regulatory inputs into the canonical RB pathway are known to be signals that contribute
to proliferative control (FIG. 4a). Inputs such as p38 MAPK phosphorylation, as well as
methylation or acetylation of RB, can serve to activate or preserve non-canonical aspects of
RB function in proliferating cells (FIG. 4b). Stress responses that activate p38 MAPK and
DNA damage signals are some of the most likely regulatory inputs that serve to mobilize RB
to sites of DNA damage, to preserve genome stability and to maintain the epigenetic state of
the cell. However, we know very little about these signals in relation to the non-canonical
RB functions described in this article and suggest that the understanding of signals that
activate the non-canonical RB pathway constitutes the most critical area of future work.

Author Manuscript

The output of canonical RB regulation is the release of E2F transcription factors from RB
upon CDK-mediated phosphorylation to activate transcriptional targets that advance the cell
cycle (FIG. 4a). The non-canonical pathway includes RB being distributed across the
genome, often in complex with E2F1, in a sequence-independent manner, where it can
engage numerous effectors such as cohesin, condensin II, BRG1, XRCC5 and XRCC6 (FIG.
4b). These serve to repair DNA, replicate DNA and ensure that chromosomes are faithfully
distributed to daughter cells. In addition, the physical association of RB with repeat elements
and enhancers allows it to silence repeat expression and control the expression of genes
involved in pluripotency to regulate lineage commitment of the cell. The mechanism by
which RB localizes to these regions and manages its many interactions and functions
remains an important gap in our understanding.
Mutations that disable the two RB pathways.
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We expect that upstream mutations affecting CDK regulation do not necessarily inactivate
non-canonical RB functions. On the basis of present knowledge, we are unable to define a
cascade of regulatory interactions analogous to the classic RB pathway (BOX 1). The best
evidence for a non-canonical tumour suppressor pathway is a mutant mouse in which RB
does not contact E2F1 through its marked box and yet the mouse is prone to develop
spontaneous cancers without apparent cell cycle disruption7. A murine mutation in the serine
protease 27 (Prss27) subunit of condensin II is also cancer prone74, as do Ezh2-mutant
strains116. However, it is difficult to connect alterations in condensin II or Ezh2 that are
contributing to cancer development directly to their impact on a non-canonical RB pathway
owing to their multiple RB-independent functions. Our present understanding of non-
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canonical functions suggests that complete loss-of-function mutations in RB1 itself are the
most reliable indicators of the lack of non-canonical RB pathway activity. Indeed, most RB1
mutations catalogued from comprehensive cancer genomic efforts are deletions or nonsense
changes that are predicted to create null alleles (cBioPortal database). This suggests that
specific interactions, or functions, unique to either canonical or non-canonical pathways are
not being specifically selected for inactivation.
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Biallelic loss of RB1 is relatively rare from a pan-cancer perspective (cBioPortal database);
however, we note that some aspects of the non-canonical pathway have been shown to be
sensitive to single-copy RB1 loss24,59,78,117, so it may be possible to specifically inactivate
non-canonical functions. Lastly, canonical and non-canonical roles may be targeted
individually in a way that is more cancer type-specific or related to disease stage or
treatment choice. On the basis of the prostate and lung cancer studies highlighted in this
article, we suggest that genes encoding components of the canonical RB pathway are
mutated early to contribute to proliferation (for example, activation of CDK4), while later
mutation of RB1 proves advantageous for transdifferentiation or other epigenetic alterations
that contribute to cancer progression or treatment resistance. Understanding these intricacies
is a critical challenge for future research.
Future outlook for research on the role of RB in cancer.
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As mentioned above, our intention with this Opinion is to create a starting point for the
grouping of chromatin-associated, non-cell-cycle-regulated functions of RB. We expect that
future investigation will determine the boundaries of this non-canonical RB pathway.
Exciting work on metabolism30,31 and related processes32,35 has established clearcut roles
for RB and E2F1 that are highly cancer relevant. Connections to the non-canonical functions
discussed here may be discovered in the future. Conceptually, the recent reports of RB
functions in the cytoplasm51,118,119 suggest that there are more cancer-relevant functions
that cannot easily be placed in either of the pathways described here (FIG. 4). This suggests
that additional RB-dependent pathways exist but remain to be fully elucidated.
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Lastly, the multifunctional properties of RB make it a critical target in many cancerrelevant
contexts. Mutations in the canonical RB pathway can trigger inappropriate cell proliferation
while leaving the RB1 gene intact and preserving the non-canonical pathway at relatively
early stages in tumorigenesis. Later in disease progression, loss of RB may fuel metastatic
dissemination through lineage alterations and genome instability, or loss of RB may allow
escape from targeted therapies. Together, the loss of both RB regulatory pathways in cancer
likely creates a powerful and synergistic cancer-promoting combination. It is exciting to see
how an improved understanding of the molecular mechanisms of action of RB is leading to a
new and better appreciation of the reasons why RB1 loss plays such a central role in human
cancer.
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The RB pathway in cancer refers to a signalling pathway in which RB is the target of
regulation by phosphorylation by cyclin D and cyclin-dependent kinase 4 (CDK4) or
CDK6, which in turn is subject to negative regulation by the CDK inhibitor 2A
(CDKN2A) and its family members4,120 (see the figure, part a). An extended view of this
pathway includes the cyclin E or cyclin A-CDK2 axis and its inhibitors (p21 and its
family). In all cases, alterations to RB regulators lead to its hyperphosphorylation and cell
cycle progression. The basic concept of this pathway is that cell cycle control is disrupted
through loss-of-function mutations in either RB1 or CDKN2A. Alternatively, gain-offunction mutations in genes encoding D-type cyclins (CCND1, CCND2 and CCND3) or
CDK4 or CDK6 constitutively phosphorylate and inactivate RB. Tabulation of genetic
alterations to this pathway have indicated that RB pathway disruption is widespread in
cancer6. Cancer genomic studies indicate that near-ubiquitous RB pathway mutations can
be found in some cancer types. The Cancer Genome Atlas data illustrating RB pathway
mutations for lung adenocarcinoma88, prostate carcinoma98, colorectal
adenocarcinoma121 and invasive breast carcinomas122 are shown (see the figure, part b).
The left-most graphs depict mutation frequency in these cancer types for the best-known
RB pathway components, whereas the right-most graphs show an expanded view of RB
regulation in which genetic alterations of all CDK inhibitors and G1 CDKs are included.
These data illustrate that the majority of lung and breast cancers possess recognizable
loss-of-function changes in RB1 and CDKN2A or gain-of-function alterations in genes
encoding D-type cyclins and associated CDKs88. Alternatively, colorectal and prostate
carcinomas show relatively few RB pathway alterations. This finding illustrates the
challenges in accounting for loss of proliferative control in some cancer types using RB
pathway mutations.
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Fig. 1 |. Canonical RB-E2F regulation and mechanisms of CDK resistance.
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a | An illustration of our definition of canonical RB function is presented. In this model,
growth factors signal the expression and activation of D-type cyclins. Cyclin D-cyclindependent kinase 4 (CDK4) or CDK6 and cyclin E-CDK2 act to hyperphosphorylate RB.
Members of the E2F family of transcription factors and their dimeric partners (DPs) are
released to activate the expression of genes that advance the cell cycle. This signalling
pathway can be blocked by CDK inhibitor 2A (CDKN2A)-mediated inhibition of cyclin D,
which is associated with CDK activity, b | RB can escape CDK hyperphosphorylation when
its RxL motif is bound by protein phosphatase 1 (PP1) or when the RxL motif is acetylated
or methylated, collectively depicted as RxL motif inhibition. This prevents substrate
recognition and ensures retention of RB function. c | RB and transcription factor E2F1 can
interact through molecular contacts that are distinct from RB and other E2F family
members. In this interaction, CDK hyperphosphorylation of RB is unable to disrupt E2F1
binding. Similarly, ultraviolet light or osmotic shock can activate p38 MAPK to
phosphorylate RB. Once phosphorylated, this stimulates E2F1 binding, even when RB is
hyperphosphorylated by CDKs. d | RB-E2F complexes can recruit chromatin-modifying
enzymes such as enhancer of zeste homologue 2 (EZH2) to mediate patterns of methylation
of histone H3 lysine 27 (H3K27me3) at promoters. RB is removed from these locations by
CDK hyperphosphorylation at the onset of S phase, but histone tail modification patterns are
preserved during DNA replication, enabling stable transmission of the epigenetic state to the
next cell generation. In the ensuing G1 phase, RB is dephosphorylated by PP1A and RBE2F recruitment of histone methyltransferase activity reinforces patterns of modification in
the ensuing cell cycle.
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Fig. 2 |.
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2F family members and extensively throughout the genome at repetitive sequences and
replication origins with transcription factor E2F1 (and likely other recruiting factors (RFs))
in a sequence-independent manner. b | The distribution of RB throughout the genome using
RFs that are not sequence-specific leaves it poised to participate at sites of DNA breaks for
non-homologous end joining (NHEJ) and homologous recombination (HR) repair in
complex with X-ray repair cross-complementing protein 5 (XRCC5), XRCC6 or
transcription activator BRG1. RB also recruits cohesin and condensin II complexes to
replicating DNA and mitotic chromosomes for condensation and segregation. Lastly, RB
directs histone deacetylation through the nucleosome-remodelling and deacetylase (NuRD)
complex and histone H3 lysine 27 trimethylation (H3K27me3) using enhancer of zeste
homologue 2 (EZH2) at repeats and enhancers. Ac, acetyl.
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Fig. 3 |. Proposed model for RB1 loss in transdifferentiation and drug resistance.
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a | RB1 gene mutation is a frequent event in acquired resistance to targeted therapies in
which the initial adenocarcinoma transdifferentiates into a neuroendocrine cancer. b |
Initially, the adenocarcinoma cells express RB, which binds to DNA regions via recruitment
factors (RFs) such as transcription factor E2F1, and use enhancer of zeste homologue 2
(EZH2) to establish histone H3 lysine 27 trimethylation (H3K27me3) and repress repeats,
including the repeat-like gene paternally expressed 10 (PEG10) and stem cell-related factors
such as transcription factor SOX2. Following treatment with a targeted agent that inhibits a
driver oncogene in the adenocarcinoma, cells that mutate RB1 are able to change
H3K27me3 patterns and express SOX2 and PEG10 to establish a new cell identity that is no
longer dependent on the therapeutic target. Treatment of resistant neuroendocrine tumours
with EZH2 inhibitors presumably reorganizes H3K27me3 and gene expression patterns,
returning cells to an epithelial state and restoring expression and sensitivity to inhibition of
the original driver oncogene. These molecular events in adenocarcinoma to neuroendocrine
transdifferentiation were established by studying prostate cancer, while only RB1 loss and
SOX2 transcription have been presently implicated in transdifferentiation of epidermal
growth factor receptor (EGFR)-mutant lung adenocarcinoma. AR, androgen receptor.
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Fig. 4 |. Features of the canonical and non-canonical RB pathways.
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a | Positive growth signals activate cyclin-dependent kinases (CDKs) to phosphorylate and
inactivate RB, whereas negative growth regulators (DNA damage and transforming growth
factor-β (TGFβ)) augment CDK inhibitors. Inactivation of RB in the canonical pathway
leads to E2F target gene transcription. b | Non-canonical RB functions are best defined by
their ambivalence to CDK regulation. Signals that likely activate non-canonical RB include
stresses that activate p38 MAPK phosphorylation and DNA damage that stimulates P300associated factor (PCAF)-dependent acetylation and SET domain-containing protein 8
(SET8; also known as KMT5A) or SET and MYND domain-containing protein (SMYD)dependent methylation. With the aid of recruitment factors (RFs), often transcription factor
E2F1, RB is capable of maintaining genome stability by localizing to sites of DNA breaks
and stimulating non-homologous end joining or homologous recombination repair in
complex with the DNA binding proteins X-ray repair cross-complementing protein 5
(XRCC5), XRCC6 or transcription activator BRG1. RB also ensures fidelity of DNA
replication and chromosome condensation through direct interactions with condensin II
complexes and the indirect influence of cohesin recruitment. Lastly, RB recruits enhancer of
zeste homologue 3 (EZH2) to trimethylate histone H3 lysine 27 (H3K27me3) and inhibit
enhancers to control lineage commitment and to silence expression of repetitive sequences.
Importantly, this diverse grouping of functions is facilitated by the association of RB with
the genome over a much larger scale than proximal promoters. DP, dimeric partner.
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